PDCD1 and cancer: In addition, neo-antigen vaccines in combination with checkpoint blockade therapies using anti-PD-1 and anti-PD-L1 antibodies showed potent therapeutic effects in patients with advanced cancer, however this therapy is in the early stages of development (271).